December 16, 2009 - Many healthcare providers who are pursuing meaningful use objectives and meeting with deadlines defined within the HITECH provision of the American Recovery and Reinvestment Act (ARRA) are challenged with securing the capital investment needed to meet the aggressive schedules.

December 16, 2009 - Non-enhanced CT for calcium detection is a reliable way to exclude obstructive coronary artery disease in patients with chest pain, according to a study published in the December issue of the American Journal of Cardiology.

December 16, 2009 – The FDA's Endocrinologic and Metabolic Drugs Advisory Committee yesterday agreed AstraZeneca established sufficient benefit with trial data showing prophylactic benefit of prescribing CRESTOR (rosuvastatin calcium) to healthy individuals to prevent heart disease.

December 16, 2009 – Patient enrollment was recently completed for a study evaluating the ability of cardiopoietic cells to restore cardiac function in heart failure patients.

December 15, 2009 – The Department of Defense (DoD) awarded a contract to Philips Healthcare for its HeartStart MRx monitor/defibrillator, which has the potential of generating more than $29 million for the company.

December 15, 2009 – CE Mark approval has been granted for Pathway Medical Technologies’ Jetstream G2TM NXT System, a peripheral atherectomy catheter for use in the treatment of PAD.

December 15, 2009 - The European Medicines Agency (EMEA) recently approved a new indication for Procoralan (ivabradine) for chronic, stable angina patients, who remain inadequately controlled despite an optimal dose of beta blockers, and whose heart rate is above 60 beats per minute.

December 14, 2009 – A new drug application (NDA) was recently submitted to the U.S. Food and Drug Administration (FDA) for ticagrelor, an investigational oral anti-platelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome (ACS).

December, 14, 2009 – A supplemental new drug application (sNDA) has been submitted to the U.S. Food and Drug Administration (FDA) for two new dosage strengths of SIMCOR, a cholesterol medication.

December 14, 2009 – First new anti-arrhythmic drug to be approved in the European Union in the last 10 years was recently granted European Commission marketing authorization.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now